| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 1078 | 2022 |
| Survival with axicabtagene ciloleucel in large B-cell lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine 389 (2), 148-157, 2023 | 214 | 2023 |
| Guidelines for the management of diffuse large B-cell lymphoma S Chaganti, T Illidge, S Barrington, P Mckay, K Linton, K Cwynarski, ... Br J Haematol 174 (1), 43-56, 2016 | 190 | 2016 |
| Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium P Quaglino, M Maule, HM Prince, P Porcu, S Horwitz, M Duvic, R Talpur, ... Annals of Oncology 28 (10), 2517-2525, 2017 | 147 | 2017 |
| The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children R Njie, AI Bell, H Jia, D Croom-Carter, S Chaganti, AD Hislop, H Whittle, ... The Journal of infectious diseases 199 (1), 31-38, 2009 | 132 | 2009 |
| Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes S Chaganti, AI Bell, NB Pastor, AE Milner, M Drayson, J Gordon, ... Blood 106 (13), 4249-4252, 2005 | 130 | 2005 |
| EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and … CP Fox, D Burns, AN Parker, KS Peggs, CM Harvey, S Natarajan, ... Bone marrow transplantation 49 (2), 280-286, 2014 | 103 | 2014 |
| A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience A Kuhnl, C Roddie, AA Kirkwood, E Tholouli, T Menne, A Patel, C Besley, ... British Journal of Haematology 198 (3), 492-502, 2022 | 88 | 2022 |
| Epstein-Barr virus infection of naive B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology E Heath, N Begue-Pastor, S Chaganti, D Croom-Carter, C Shannon-Lowe, ... PLoS pathogens 8 (5), e1002697, 2012 | 87 | 2012 |
| Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence S Chaganti, EM Heath, W Bergler, M Kuo, M Buettner, G Niedobitek, ... Blood, The Journal of the American Society of Hematology 113 (25), 6372-6381, 2009 | 85 | 2009 |
| Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma C Roddie, L Neill, W Osborne, S Iyengar, E Tholouli, D Irvine, S Chaganti, ... Blood Advances 7 (12), 2872-2883, 2023 | 79 | 2023 |
| Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease … S Chaganti, CS Ma, AI Bell, D Croom-Carter, AD Hislop, SG Tangye, ... Blood, The Journal of the American Society of Hematology 112 (3), 672-679, 2008 | 69 | 2008 |
| Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT DM Burns, S Rana, E Martin, S Nagra, J Ward, H Osman, AI Bell, P Moss, ... Bone marrow transplantation 51 (6), 825-832, 2016 | 56 | 2016 |
| Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies E Nikolousis, S Nagra, S Paneesha, J Delgado, K Holder, L Bratby, ... Annals of hematology 89 (11), 1141-1145, 2010 | 56 | 2010 |
| The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper P McKay, MR Wilson, S Chaganti, J Smith, CP Fox, K Cwynarski, ... British journal of haematology 190 (5), 708-714, 2020 | 47 | 2020 |
| Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event DM Burns, R Tierney, C Shannon-Lowe, J Croudace, C Inman, B Abbotts, ... Blood, The Journal of the American Society of Hematology 126 (25), 2665-2675, 2015 | 42 | 2015 |
| Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell … FL Locke, DB Miklos, C Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... Blood 138, 2, 2021 | 37 | 2021 |
| Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England A Kuhnl, C Roddie, N Martinez-Cibrian, TF Menne, K Linton, S Lugthart, ... Blood 134, 767, 2019 | 37 | 2019 |
| Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic … E Nikolousis, S Robinson, S Nagra, C Brookes, F Kinsella, S Tauro, ... Leukemia research 37 (5), 561-565, 2013 | 37 | 2013 |
| Management of secondary central nervous system lymphoma. K Cwynarski, T Cummin, W Osborne, J Lewis, S Chaganti, J Smith, ... British Journal of Haematology 200 (2), 2023 | 34* | 2023 |
